Pfizer announces availability of new ADHD drug

NEW YORK — A new drug for treating attention deficit hyperactivity disorder made by Pfizer is now available, the drug maker said.

Pfizer announced the availability of Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension, calling it the first once-per-day, extended-release liquid formulation of methylphenidate. The Food and Drug Administration approved the drug in September 2012.

"In order to effectively treat patients with chronic conditions such as ADHD, it is important to consider individual patient needs, including options for medication administration," Center for Psychiatry and Behavioral Medicine president and laboratory classroom study investigator Ann Childress said. "As the first once-daily, extended-release liquid medication for patients with ADHD, Quillivant XR represents a new alternative to other ADHD treatments."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.